September 30, 2021
In an interview with Targeted Oncology™,Phillip Koo, MD, discusses both the role of novel PSMA tracers in prostate cancer imaging and the promise that theranostics, including LuPSMA, hold for prostate cancer therapy.
The success noted during the VISION trial created another exciting possibility—that theranostics such as focusing onPSMA might not only detect, but also treat, prostate cancer. Although investigators studied the drug in a specific population of patients with late stage, highly pretreated prostate cancer, clinicians and researchers who have reviewed the trial’s results have become excited about the possibility of using theranostics to treat men given a diagnosis of this disease at earlier disease states such as the hormone sensitive setting.
In the second interview of the series, Phillip Koo, MD, chief of Diagnostic Imaging and physician executive at Banner MD Anderson Cancer Center, discusses both the role of novel PSMA tracers in prostate cancer imaging and the promise that theranostics like LuPSMA holds for prostate cancer therapy.
Read more here> targetedonc.com/view/new-ho...
Aggressive Variant Prostate Cancer (AVPC)
Very interesting article. Prostate cancer 'cured' by shocking prostate cancer with testosterone.
The Proper Role Of Medical Marijuana in Prostate Cancer Treatment
I am in need of treatment advice for my Prostate cancer
